Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous UCB for Neonatal HIE and Anemia
NCT03352310Phase 1Unknown
- Sponsor
- Mononuclear Therapeutics Limited
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous umbilical cord blood in hypoxic-ischemic encephalopathy (HIE) and neonatal anemia (2 arms), sponsored by Mononuclear Therapeutics Limited. Primary endpoints: HIE: Mortality at 6 months and Anemia: Change from Baseline Hematocrit at 6 months. Status: unknown.
02
Drugs
autologous umbilical cord blood
03
Conditions
hypoxic-ischemic encephalopathy (HIE)neonatal anemia
Beyond the preview
Go deeper on NCT03352310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352310.